Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
by Zacks Equity Research
Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Q1 Earnings Review
by Zacks Equity Research
Q1 Earnings Review
Markets Try to Shake Off April Blues
by Mark Vickery
Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 2.08% and 1.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Markets Mixed as Q1 Earnings, Powell Control News Headlines
by Mark Vickery
Wednesday morning brings us more Q1 earnings reports, including from Abbott Labs (ABT) and U.S. Bancorp (USB).
3 Buy Rated Stocks to Consider as Earnings Approach
by Shaun Pruitt
Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
Ahead of Abbott (ABT) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Abbott (ABT) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $112.44, representing a +1.74% change from its previous close.
HAE vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services
by Zacks Equity Research
T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?